Nothing Special   »   [go: up one dir, main page]

ITMI20021527A1 - Anticorpi anti componente c5 del complemento e loro uso - Google Patents

Anticorpi anti componente c5 del complemento e loro uso

Info

Publication number
ITMI20021527A1
ITMI20021527A1 IT2002MI001527A ITMI20021527A ITMI20021527A1 IT MI20021527 A1 ITMI20021527 A1 IT MI20021527A1 IT 2002MI001527 A IT2002MI001527 A IT 2002MI001527A IT MI20021527 A ITMI20021527 A IT MI20021527A IT MI20021527 A1 ITMI20021527 A1 IT MI20021527A1
Authority
IT
Italy
Prior art keywords
complement
antibodies
nucleotide sequences
invention refers
present
Prior art date
Application number
IT2002MI001527A
Other languages
English (en)
Inventor
Roberto Marzari
Francesco Tedesco
Original Assignee
Consiglio Nazionale Ricerche
Univ Degli Studi Trieste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche, Univ Degli Studi Trieste filed Critical Consiglio Nazionale Ricerche
Priority to IT2002MI001527A priority Critical patent/ITMI20021527A1/it
Priority to PT03763792T priority patent/PT1529063E/pt
Priority to DK03763792.3T priority patent/DK1529063T3/da
Priority to AT03763792T priority patent/ATE506375T1/de
Priority to PCT/EP2003/007487 priority patent/WO2004007553A1/en
Priority to SI200332009T priority patent/SI1529063T1/sl
Priority to AU2003246676A priority patent/AU2003246676A1/en
Priority to ES03763792T priority patent/ES2365217T3/es
Priority to DE60336821T priority patent/DE60336821D1/de
Priority to US10/521,109 priority patent/US7999081B2/en
Priority to EP03763792A priority patent/EP1529063B1/en
Publication of ITMI20021527A1 publication Critical patent/ITMI20021527A1/it
Priority to CY20111100665T priority patent/CY1111703T1/el
Priority to US13/185,478 priority patent/US8282929B2/en
Priority to US13/611,910 priority patent/US8962819B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
IT2002MI001527A 2002-07-11 2002-07-11 Anticorpi anti componente c5 del complemento e loro uso ITMI20021527A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT2002MI001527A ITMI20021527A1 (it) 2002-07-11 2002-07-11 Anticorpi anti componente c5 del complemento e loro uso
ES03763792T ES2365217T3 (es) 2002-07-11 2003-07-10 Anticuerpos anti componente c5 del sistema de complemento y su uso.
DE60336821T DE60336821D1 (de) 2002-07-11 2003-07-10 Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
AT03763792T ATE506375T1 (de) 2002-07-11 2003-07-10 Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
PCT/EP2003/007487 WO2004007553A1 (en) 2002-07-11 2003-07-10 Antibodies anti-c5 component of the complement system and their use
SI200332009T SI1529063T1 (sl) 2002-07-11 2003-07-10 Protitelesa proti C5 komponenti komplementnega sistema in njihova uporaba
AU2003246676A AU2003246676A1 (en) 2002-07-11 2003-07-10 Antibodies anti-c5 component of the complement system and their use
PT03763792T PT1529063E (pt) 2002-07-11 2003-07-10 Anticorpos anti-componente c5 do sistema de complemento e sua utilização
DK03763792.3T DK1529063T3 (da) 2002-07-11 2003-07-10 Antistoffer anti-C5-komponent af komplementsystemet og deres anvendelse
US10/521,109 US7999081B2 (en) 2002-07-11 2003-07-10 Anti-C5 alpha antibodies
EP03763792A EP1529063B1 (en) 2002-07-11 2003-07-10 Antibodies anti-c5 component of the complement system and their use
CY20111100665T CY1111703T1 (el) 2002-07-11 2011-07-08 Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους
US13/185,478 US8282929B2 (en) 2002-07-11 2011-07-18 Methods of treating a disease with anti-C5 alpha antibodies
US13/611,910 US8962819B2 (en) 2002-07-11 2012-09-12 Anti-C5 alpha antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001527A ITMI20021527A1 (it) 2002-07-11 2002-07-11 Anticorpi anti componente c5 del complemento e loro uso

Publications (1)

Publication Number Publication Date
ITMI20021527A1 true ITMI20021527A1 (it) 2004-01-12

Family

ID=30012505

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001527A ITMI20021527A1 (it) 2002-07-11 2002-07-11 Anticorpi anti componente c5 del complemento e loro uso

Country Status (12)

Country Link
US (3) US7999081B2 (it)
EP (1) EP1529063B1 (it)
AT (1) ATE506375T1 (it)
AU (1) AU2003246676A1 (it)
CY (1) CY1111703T1 (it)
DE (1) DE60336821D1 (it)
DK (1) DK1529063T3 (it)
ES (1) ES2365217T3 (it)
IT (1) ITMI20021527A1 (it)
PT (1) PT1529063E (it)
SI (1) SI1529063T1 (it)
WO (1) WO2004007553A1 (it)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
DE602005025347D1 (de) 2004-01-30 2011-01-27 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
PT2061810E (pt) * 2006-09-05 2015-02-05 Alexion Pharma Inc Métodos e composições para o tratamento de neuropatias mediadas por anticorpos
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2469283B1 (en) * 2006-09-08 2014-01-15 The Chancellor, Masters and Scholars of the University of Oxford Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2815766B1 (en) * 2008-08-05 2017-07-05 Novartis AG Compositions and methods for antibodies targeting complement protein C5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
CA2896413A1 (en) 2008-12-05 2010-06-10 Abraxis Bioscience Llc Sparc binding peptides and uses thereof
KR20120041175A (ko) * 2009-05-14 2012-04-30 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 미량 존재하는 인간 혈장 단백질 바이오마커의 신규 패널을 이용한 간성 섬유증의 임상적 진단
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
WO2012178083A1 (en) 2011-06-22 2012-12-27 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
BR112014020427B1 (pt) 2012-02-20 2023-04-04 Swedish Orphan Biovitrum Ab (Publ) Polipeptídeo de ligação de c5, composto de ligação de c5 e combinação
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
WO2014049073A1 (en) 2012-09-27 2014-04-03 Octapharma Ag Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
AU2013344462B2 (en) 2012-11-15 2018-07-12 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
US10254288B2 (en) * 2013-08-16 2019-04-09 Quidel Corporation Method for species-independent measurement of complement activation in animals
LT3038633T (lt) 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
LT3039033T (lt) 2013-08-28 2019-10-25 Affibody Ab Surišantys polipeptidai, turintys mutuotą karkasą
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
IL258525B2 (en) 2015-10-07 2023-03-01 Apellis Pharmaceuticals Inc Dosing regimens
JP6390647B2 (ja) * 2016-03-10 2018-09-19 株式会社豊田自動織機 永久磁石式回転電機
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Antibodies against C5 and their uses
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
JP7096240B2 (ja) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合ｃ５の定量化方法
MX2019007749A (es) 2017-01-31 2019-09-09 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
JP7133561B2 (ja) 2017-03-01 2022-09-08 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害の治療のためのアリール、ヘテロアリール及び複素環式医薬化合物
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
KR20240115904A (ko) 2018-08-01 2024-07-26 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
CN112839945A (zh) 2018-09-06 2021-05-25 艾其林医药公司 补体因子d抑制剂的形态形式
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
JP7437261B2 (ja) 2019-07-31 2024-02-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
CN114466660A (zh) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
MX2022001896A (es) 2019-08-16 2022-06-02 Regeneron Pharma Formulaciones anti-c5 de alta concentracion.
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
EP4048691A1 (en) 2019-10-25 2022-08-31 Regeneron Pharmaceuticals, Inc. Dosing regimens for treating or preventing c5-associated diseases
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
CN115667925A (zh) 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso

Also Published As

Publication number Publication date
SI1529063T1 (sl) 2011-08-31
US20060115476A1 (en) 2006-06-01
WO2004007553A8 (en) 2004-04-29
US8962819B2 (en) 2015-02-24
CY1111703T1 (el) 2015-10-07
US8282929B2 (en) 2012-10-09
EP1529063B1 (en) 2011-04-20
US20130071922A1 (en) 2013-03-21
AU2003246676A8 (en) 2004-02-02
AU2003246676A1 (en) 2004-02-02
US20120009184A1 (en) 2012-01-12
PT1529063E (pt) 2011-07-25
ES2365217T3 (es) 2011-09-26
DE60336821D1 (de) 2011-06-01
DK1529063T3 (da) 2011-06-20
WO2004007553A1 (en) 2004-01-22
EP1529063A1 (en) 2005-05-11
US7999081B2 (en) 2011-08-16
ATE506375T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
TW200744642A (en) Novel peptides for use in the treatment of obesity
PE20130314A1 (es) PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO
WO2008050329A3 (en) Novel sirnas and methods of use thereof
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
WO2006048450A3 (en) Peptides for use in the treating obesity
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2006048452A3 (en) Peptides for use in treating of obesity
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
NO20052956L (no) Defensinprotiner
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
FR2858234B1 (fr) Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
CL2019000236A1 (es) Composición y uso de un péptido.